CHA ÀǰúÇдëÇб³ Â÷º´¿ø professor

±³¼ö´Ô»çÁø
  • À̼¼Èñ
  • ¼Ò ¼Ó: ºÐ´çÂ÷º´¿ø
  • Àü¹®ºÐ¾ß : È£Èí±âÁúȯ
  • Á÷ À§: Á¶±³¼ö
  • ¸Þ ÀÏ: ºñ°ø°³
  • Àü È­: 1577-4488
  • ÆÑ ½º:
  • ÁÖ ¼Ò: °æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßžµ¿ 351¹øÁö
  • ȨÆäÀÌÁö:
  • ·Î±×ÀÎ

ÅǸ޴º

ÁÖ¿ä¹ßÇ¥³í¹®

ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£ ±¸ºÐ Á¦¸ñ
63 (±¹¿Ü)SCI Longitudinal Lung Volume Changes in Patients with Chronic Obstructive Pulmonary Disease
62 (±¹³»)SCOPUS Endobronchial Metastases from Extrathoracic Malignancies: Recent 10 Years' Experience in a Single University Hospital
61 (±¹³»)SCOPUS Endobronchial Metastases from Extrathoracic Malignancies: Recent 10 Years' Experience in a Single University Hospital
60 (±¹¿Ü)SCI Impact of Diabetes on Treatment Outcomes and Long-Term Survival in Multidrug-Resistant Tuberculosis
59 (±¹¿Ü)SCI Simvastatin inhibitis induction of matrix methalloproteinase-9 in rat alveolar macrophages exposed to cigarette smoke extract
58 (±¹¿Ü)SCI Bortezomib alleviates experimental pulmonary arterial hypertension.
57 (±¹¿Ü)SCI Inhaled corticosteroid is associated with an increased risk of tuberculosis in patients with chronic obstructive pulmonary disease.
56 (±¹¿Ü)SCI CHRNA3 Variant for Lung Cancer Is Associated with Chronic Obstructive Pulmonary Disease in Korea
55 (±¹¿Ü)SCI Exertional Desaturation as a Predictor of Rapid Lung Function Decline in COPD
54 (±¹³»)KCIÈĺ¸ Gadolinium Á¶¿µÁ¦¿Í °æ±¸ propranolol À» »ç¿ëÇÑ È¯ÀÚ¿¡¼­ ¹ß»ýÇÑ ±Þ¼º È£Èí°ï¶õÁõÈıºÀ» µ¿¹ÝÇÏ´Â ¾Æ³ªÇʶô½Ã¾ç ¹ÝÀÀ 1¿¹
ÀÌÀüÆäÀÌÁö À̵¿ 11 12 13 14 15 16 17 18 ´ÙÀ½ÆäÀÌÁö À̵¿
Copyright ¨Ï chamc, All rights reserved.

ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à

  • °­³²Â÷º´¿ø
  • ºÐ´çÂ÷º´¿ø
  • ºÐ´çÂ÷¿©¼ºº´¿ø
  • ±¸¹ÌÂ÷º´¿ø
  • ¿©¼ºÀÇÇבּ¸¼Ò
  • Â÷¿ò

ÀüÈ­¹®ÀÇ

  • °­³²Â÷º´¿ø 02.3468.3000
  • ºÐ´çÂ÷º´¿ø 031.780.5000
  • Â÷¿ò 02.3015.5300
  • ±¸¹ÌÂ÷º´¿ø 054.450.9700
  • ´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
  • °­³²°ÇÁø¼¾ÅÍ 02.2191.3900
  • ºÐ´çÁ¾Çհǰ­ÁõÁø¼¾ÅÍ 031.780.5940
  • ½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
  • ±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
  • ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729